Explore this test

  • Test Details
  • Lab Values
  • Clinical Significance
  • Treatment Options
DOWNLOAD SPECIMEN PREP FLYER

Explore this test

Test Code 251(Includes total cholesterol, HDL and non-HDL)

Test Details

Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)

Non-HDL-C is a calculation that represents the cholesterol carried by all atherogenic particles including:

  • Chylomicron remnants
  • VLDL
  • IDL
  • LDL
  • Lp(a)

Methodology

Non-HDL-C is calculated as follows:
Non-HDL-C = Total cholesterol – High-density cholesterol

Patient Preparation

8-12 hour fast prior to collection. Patient may drink water only.

Preferred Specimen

1.0 mL serum (0.5 mL minimum) collected in serum separator tube (SST/Tiger Top)

Alternate Specimen

1.0 mL EDTA plasma (0.5 mL minimum) collected in plasma separator tube (Pearl Top)

Transport Temperature

Refrigerated (ship on frozen cold packs)

Stability

Refrigerated: 7 days

Lab Values

Lab Values

Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)

Age Optimal Borderline Increased Risk
≤18 yrs <120 mg/dL 120 – 144 mg/dL >144 mg/dL
>18 yrs with CVD <100 mg/dL 100 – 130 mg/dL >130 mg/dL
>18 yrs without CVD <130 mg/dL 130 – 190 mg/dL >190 mg/dL

 

Test Details
Clinical Significance

Clinical Significance

Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)

  • When TGs are high, LDL-C does not accurately reflect the amount of circulating atherogenic particles.  In this situation, non-HDL-C may be a better predictor of CVD risk than LDL-C.1-2
  • Non-HDL-C has been shown in many studies to be superior to calculated LDL-C in predicting heart disease risk.1-2

References:

  1. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49-73.
  2. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49-73.
Lab Values
Treatment Options

Treatment Options

Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)

  • Lifestyle modification
  • Statins
  • Niacin
  • Fibrates
  • Omega-3 Fatty Acids
  • Bile acid sequestrants
  • Cholesterol absorption inhibitors
Clinical Significance